Soft Tissue Sarcoma, Version 1.2021 Featured Updates to the NCCN Guidelines

The major changes to the 2012 and 2011 NCCN Guidelines for Soft Tissue Sarcoma pertain to the management of patients with gastrointestinal stromal tumors (GISTs) and desmoid tumors (aggressive fibromatosis). Postoperative imatinib following complete resection for primary GIST with no preoperative imatinib is now included as a category 1 recommendation for patients with intermediate or high risk of recurrence. The panel also reaffirmed the recommendation for preoperative use of imatinib in patients with GISTs that are resectable with negative margins but associated with significant surgical morbidity. Observation was included as an option for patients with resectable desmoid tumors that are small and asymptomatic, not causing morbidity, pain, or functional limitation. Sorafenib is included as an option for systemic therapy for patients with desmoid tumors.

[1]  W. Blattner,et al.  A cancer family syndrome in twenty-four kindreds. , 1988, Cancer research.

[2]  M. Posner,et al.  The desmoid tumor. Not a benign disease. , 1989, Archives of surgery.

[3]  L. Strong,et al.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.

[4]  R. Benjamin,et al.  Combination chemotherapy in adult desmoid tumors , 1993, Cancer.

[5]  N. Kemeny,et al.  Successful treatment of a desmoid tumor with doxorubicin , 1993, Cancer.

[6]  J. Tepper,et al.  Intraoperative radiotherapy in retroperitoneal sarcomas. Final results of a prospective, randomized, clinical trial. , 1993, Archives of surgery.

[7]  G. Petersen,et al.  Desmoid tumours in familial adenomatous polyposis. , 1994, Gut.

[8]  C. Catton,et al.  Outcome and prognosis in retroperitoneal soft tissue sarcoma. , 1994, International journal of radiation oncology, biology, physics.

[9]  M. Baum,et al.  Management of desmoid tumours including a case report of toremifene. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  P. Kleihues,et al.  Tumors associated with p53 germline mutations: a synopsis of 91 families. , 1997, The American journal of pathology.

[11]  J. Fraumeni,et al.  The epidemiology of soft tissue sarcoma. , 1997, Seminars in oncology.

[12]  J M Woodruff,et al.  Prognostic factors associated with long-term survival for retroperitoneal sarcoma: implications for management. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  S. Hirota,et al.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.

[14]  M. Ballo,et al.  Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  R. DeMatteo,et al.  Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. , 2000, Annals of surgery.

[16]  Yuh‐Cheng Yang,et al.  Successful treatment of recurrent pelvic desmoid tumour with tamoxifen: case report. , 2000, Human reproduction.

[17]  L. Anderson,et al.  High-dose-rate intraoperative radiation therapy (HDR-IORT) for retroperitoneal sarcomas. , 2000, International journal of radiation oncology, biology, physics.

[18]  C. Wiltschke,et al.  Treatment of extra‐abdominal desmoid tumors with interferon‐alpha with or without tretinoin , 2000, Journal of surgical oncology.

[19]  J. Fraumeni,et al.  Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[20]  D. Rattner,et al.  Long-term results of intraoperative electron beam radiotherapy for primary and recurrent retroperitoneal soft tissue sarcoma. , 2001, International journal of radiation oncology, biology, physics.

[21]  P. Casali,et al.  Low‐dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis , 2001, Cancer.

[22]  C. Stratakis,et al.  Familial paraganglioma and gastric stromal sarcoma: a new syndrome distinct from the Carney triad. , 2002, American journal of medical genetics.

[23]  A. D. Van den Abbeele,et al.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.

[24]  O. S. Nielsen,et al.  Treatment of aggressive fibromatosis: A retrospective study of 72 patients followed for 1-27 years , 2002, Acta orthopaedica Scandinavica.

[25]  D. Sargent,et al.  Use of intraoperative electron beam radiotherapy in the management of retroperitoneal soft tissue sarcomas. , 2002, International journal of radiation oncology, biology, physics.

[26]  R. Eeles,et al.  Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. , 2003, Cancer research.

[27]  K. Hunt,et al.  Phase I trial of preoperative concurrent doxorubicin and radiation therapy, surgical resection, and intraoperative electron-beam radiation therapy for patients with localized retroperitoneal sarcoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Samuel Singer,et al.  PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors , 2003, Science.

[29]  P. Romestaing,et al.  Surgical management of retroperitoneal sarcomas associated with external and intraoperative electron beam radiotherapy. , 2003, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[30]  S. Hirota,et al.  Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. , 2003, Gastroenterology.

[31]  B. Eisenberg,et al.  Surgery and Imatinib in the Management of GIST: Emerging Approaches to Adjuvant and Neoadjuvant Therapy , 2004, Annals of Surgical Oncology.

[32]  A. Hansmann,et al.  High‐dose tamoxifen and sulindac as first‐line treatment for desmoid tumors , 2004, Cancer.

[33]  B. Bui,et al.  [Comparison of intensity-modulated postoperative radiotherapy with conventional postoperative conformal radiotherapy for retroperitoneal sarcoma]. , 2004, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

[34]  D. S. Lind,et al.  Adjuvant Radiation Therapy for Resectable Retroperitoneal Soft Tissue Sarcoma: The University of Florida Experience , 2005, American journal of clinical oncology.

[35]  N. Lindor,et al.  Desmoid Tumors – a Characterization of Patients Seen at Mayo Clinic 1976–1999 , 2005, Familial Cancer.

[36]  C. Antonescu,et al.  Adjuvant imatinib mesylate in patients with primary high risk gastrointestinal stromal tumor (GIST) following complete resection: Safety results from the U.S. Intergroup Phase II trial ACOSOG Z9000 , 2005 .

[37]  T. Pawlik,et al.  Long-Term Results of Two Prospective Trials of Preoperative External Beam Radiotherapy for Localized Intermediate- or High-Grade Retroperitoneal Soft Tissue Sarcoma , 2006, Annals of Surgical Oncology.

[38]  S. Bülow,et al.  Familial adenomatous polyposis (FAP): Genotype correlation to FAP phenotype with osteomas and sebaceous cysts , 2006, American journal of medical genetics. Part A.

[39]  I. Blanco,et al.  [Familial adenomatous polyposis]. , 2006, Gastroenterologia y hepatologia.

[40]  M. Heslin,et al.  Preoperative radiation therapy with selective dose escalation to the margin at risk for retroperitoneal sarcoma , 2006, Cancer.

[41]  R. DeMatteo,et al.  Combined Surgical and Molecular Therapy: The Gastrointestinal Stromal Tumor Model , 2006, Annals of surgery.

[42]  J. Blay,et al.  KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. , 2006, European journal of cancer.

[43]  M. Tucker,et al.  Risk of soft tissue sarcomas by individual subtype in survivors of hereditary retinoblastoma. , 2007, Journal of the National Cancer Institute.

[44]  K. Owzar,et al.  Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): A meta-analyis based on 1,640 patients (pts) , 2007 .

[45]  C. Catton,et al.  Initial results of a trial of preoperative external-beam radiation therapy and postoperative brachytherapy for retroperitoneal sarcoma , 2002, Annals of Surgical Oncology.

[46]  K. Owzar,et al.  Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  S. Singer,et al.  Impact of intensity-modulated radiation therapy on local control in primary soft-tissue sarcoma of the extremity. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  J. Fletcher,et al.  Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  J. Blay,et al.  Extra-abdominal primary fibromatosis: Aggressive management could be avoided in a subgroup of patients. , 2008, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[50]  J. Ellison,et al.  Clinical and molecular genetics of patients with the Carney–Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD , 2008, European Journal of Human Genetics.

[51]  H. Joensuu.  Risk stratification of patients diagnosed with gastrointestinal stromal tumor. , 2008, Human pathology.

[52]  P. Thall,et al.  A Randomized, Phase II Study of Preoperative plus Postoperative Imatinib in GIST: Evidence of Rapid Radiographic Response and Temporal Induction of Tumor Cell Apoptosis , 2008, Annals of Surgical Oncology.

[53]  C. Antonescu,et al.  Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. , 2009, The Lancet. Oncology.

[54]  G. Demetri,et al.  Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665 , 2009, Journal of surgical oncology.

[55]  C. Beauchamp.  A critical analysis of treatment strategies in desmoid tumours: a review of a series of 106 cases , 2009 .

[56]  C. Antonescu,et al.  Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial , 2009, The Lancet.

[57]  B. Bui,et al.  A critical analysis of treatment strategies in desmoid tumours: a review of a series of 106 cases. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[58]  L. Mariani,et al.  Desmoid-Type Fibromatosis: A Front-Line Conservative Approach to Select Patients for Surgical Treatment , 2009, Annals of Surgical Oncology.

[59]  P. Casali,et al.  Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST). , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[60]  C. Antonescu,et al.  Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations , 2010, Proceedings of the National Academy of Sciences.

[61]  Dafydd G. Thomas,et al.  Efficacy of Imatinib in Aggressive Fibromatosis: Results of a Phase II Multicenter Sarcoma Alliance for Research through Collaboration (SARC) Trial , 2010, Clinical Cancer Research.

[62]  J. Blay,et al.  Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial , 2011, BMC Cancer.

[63]  D. Sahani,et al.  Proton-Beam, Intensity-Modulated, and/or Intraoperative Electron Radiation Therapy Combined with Aggressive Anterior Surgical Resection for Retroperitoneal Sarcomas , 2010, Annals of Surgical Oncology.

[64]  A. Chou,et al.  Immunohistochemistry for SDHB Divides Gastrointestinal Stromal Tumors (GISTs) into 2 Distinct Types , 2010, The American journal of surgical pathology.

[65]  C. Antonescu,et al.  NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

[66]  C. Antonescu,et al.  Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor) , 2010, Cancer.

[67]  G. Nielsen,et al.  An effective preoperative three-dimensional radiotherapy target volume for extremity soft tissue sarcoma and the effect of margin width on local control. , 2010, International journal of radiation oncology, biology, physics.

[68]  Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  H. Järvinen,et al.  Family History, Surgery, and APC Mutation Are Risk Factors for Desmoid Tumors in Familial Adenomatous Polyposis: An International Cohort Study , 2011, Diseases of the colon and rectum.

[70]  C. Antonescu,et al.  Activity of Sorafenib against Desmoid Tumor/Deep Fibromatosis , 2010, Clinical Cancer Research.

[71]  J. Blay,et al.  Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[72]  M. O'sullivan,et al.  SDHB immunohistochemistry: a useful tool in the diagnosis of Carney–Stratakis and Carney triad gastrointestinal stromal tumors , 2011, Modern Pathology.

[73]  M. Robson,et al.  Inherited gastrointestinal stromal tumor syndromes: mutations, clinical features, and therapeutic implications , 2012, Clinical Sarcoma Research.

[74]  O. Dekkers,et al.  A nation‐wide study comparing sporadic and familial adenomatous polyposis‐related desmoid‐type fibromatoses , 2011, International journal of cancer.

[75]  G. Demetri,et al.  Follow-up results after 9 years (yrs) of the ongoing, phase II B2222 trial of imatinib mesylate (IM) in patients (pts) with metastatic or unresectable KIT+ gastrointestinal stromal tumors (GIST). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  M. Olivier,et al.  Sarcomas in TP53 germline mutation carriers , 2012, Cancer.

[77]  Aki Vehtari,et al.  One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. , 2012, JAMA.

[78]  R. Slopsema,et al.  Comparison of three-dimensional (3D) conformal proton radiotherapy (RT), 3D conformal photon RT, and intensity-modulated RT for retroperitoneal and intra-abdominal sarcomas. , 2012, International journal of radiation oncology, biology, physics.

[79]  David M. Thomas,et al.  High Frequency of Germline TP53 Mutations in a Prospective Adult-Onset Sarcoma Cohort , 2013, PloS one.

[80]  A. Kambadakone,et al.  Surgical placement of biologic mesh spacers prior to external beam radiation for retroperitoneal and pelvic tumors. , 2013, Practical radiation oncology.

[81]  P. Terrier,et al.  Should adjuvant radiotherapy be administered in addition to front-line aggressive surgery (FAS) in patients with primary retroperitoneal sarcoma? , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.